Monocentric, open-label, single-arm, phase I/II clinical trial to evaluate the use of the ONCOGREEN galenic formulation consisting of indocyanine green (ICG) with autologous extracellular vesicles (EVs) for in vivo diagnostics of solid neoplasms undergoing surgical removal
Phase: Phase I-II clinical trials
Principal Investigator: Prof. Mazzaferro Vincenzo
Main Facility: Chirurgia Generale Oncologica 1 – Epato-Gastro-Pancreatica e Trapianto di Fegato
Drug: ONCOGREEN galenic formulation
Pathologies: Mesenchymal tumors in adults (sarcoma, GIST, others)
ClinicalTrials.gov: Read more about clinical trials
The ONCOGREEN study is a monocentric, open-label, single-arm phase I/II clinical trial designed to evaluate the safety and diagnostic performance of a galenic formulation called OncoGreen, consisting of indocyanine green (ICG) combined with autologous extracellular vesicles (EVs).
Extracellular vesicles are isolated from the patient’s plasma through plasmapheresis, loaded with ICG, and then reinfused intravenously. During surgery, fluorescence imaging allows the dye to highlight tumor tissue and margins, potentially improving intraoperative visualization and tumor removal.
Phase I aims to assess safety, tolerability and determine the optimal dose, while Phase II evaluates the effectiveness of the technique in improving intraoperative tumor visualization
Last update: 20/04/2026